Active Biotech AB Year-end report January - December 2013

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Active Biotech AB Year-end report January - December 2013

Laquinimod * Teva remains committed to the development of laquinimod (NERVENTRA(®)) for the treatment of multiple sclerosis (MS) * On January 24, laquinimod received a negative opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The CHMP's opinion was based on the view that laquinimod's positive effect on reducing relapses did not outweigh the potential risks. Although the CHMP found that laquinimod has a positive effect on slowing disability in MS patients, this finding had no impact on the decision. In the risk assessment, the CHMP focused on findings in animal studies, performed in parallel with the pivotal clinical trials, relating to the potential risk of fetal damage and the potential increased risk of cancer. None of these effects have been observed in the comprehensive patient material, comprising 7,490 patient years in total, with some patients being exposed for more than seven years and tolerated treatment well. * Teva has requested a re-examination of the CHMP's opinion. * The ongoing pivotal Phase III study CONCERTO continues according to plan. Results are expected 2016. * Teva plans to initiate clinical trials in primary progressive multiple sclerosis (PPMS). * Analysis of data from the Phase III ALLEGRO study shows that laquinimod provides a beneficial impact on brain tissue damage. Laquinimod-treated patients accumulated significantly less brain tissue damage caused by neurodegeneration. * Data presented at ECTRIMS shows that laquinimod reduces inflammation and has neuroprotective activity. * At this time, Teva has decided to postpone further clinical development of laquinimod for the treatment of Crohn's disease until a clearer clinical strategy has been defined. Tasquinimod * Active Biotech received a milestone payment of EUR 12 M from Ipsen. * Phase III 10TASQ10 study is proceeding as planned; the primary analysis of progression-free survival (PFS) and overall survival (OS) is expected in 2014. * In February 2014, Ipsen launched a randomized, double-blind, placebo- controlled Phase III study of tasquinimod in chemo-naive CRPC patients in Asia. ANYARA * Detailed analysis provided further support for ANYARA's efficacy in a biomarker-defined sub-group of renal cell cancer patients. Results from the Phase II/III study was presented at the 2013 European Cancer Congress. * The next step is a pivotal trial to treat a biomarker-defined group of renal cancer patients in second-line therapy, which will commence only when an out-licensing agreement has been reached with a partner. Paquinimod (57-57) * Evaluation of the clinical trial in systemic sclerosis demonstrated a favorable safety profile and effects on disease-related biomarkers. * The next step in the development program is a Phase II study in systemic sclerosis, which will commence only when an out-licensing agreement has been reached with a partner. ISI * Project proceeding according to plan.  For further information, please contact:   Tomas Leanderson, President and CEO Active Biotech AB   Tel: +46 (0)46 19 20 95 (Corp. Reg. No. 556223-9227)   Box 724, SE-220 07 Lund   Hans Kolam, CFO Tel: +46 (0)46 19 20 00   Tel: +46 (0)46 19 20 44 Fax: +46 (0)46 19 11 00  The report is also available at www.activebiotech.com [HUG#1761651]

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Data Breach at Lumara Bio: Privacy Lawsuits Loom

Updated Category News Views 262

Another Day, Another Data Breach It seems like you can’t throw a stone without hitting a data breach these days—and this time, it’s Lumara Bio USA’s turn under the spotlight. The Princeton-based oncology therapeutics outfit, part of Germany’s ITM Isotope Technologies, spilled some beans it never meant to. We're talking some pretty sensitive stuff here, folks....

Continue Reading
Pencil Reinvention Aims to Reduce Classroom Waste

Updated Category News Views 28

Sharpen Those Ideas: Reinventing the Humble Pencil Every classroom has 'em: pencils chewed up faster than a kid chomping through bubblegum. This ain't new. But dig this—a Chicago teacher's coming in hot with a tweak to extend pencil life. How? By addressing the ol' crumbly eraser issue. You know, the kind that vanishes into thin air right when you need it most. So,...

Continue Reading
VeriSilicon's GLTiny: Game-Changer for Wearable Tech

Updated Category News Views 58

Revolutionizing Wearable Graphics with GLTiny There's a fresh breeze blowing through the world of wearable tech, and VeriSilicon's GLTiny seems to be at the heart of it. When the silicon giant out of Shanghai tossed GLTiny into the mix, it wasn't just throwing another chip on the barbie. Oh no, this is a real pivot towards juicing up those smart gadgets strapped to your...

Continue Reading
2026 Global Ocean Forum Unveils Key Marine Strategies

Updated Category News Views 73

Riding the Waves in Qingdao It ain't every day that a talk-fest dedicated to oceans gets my attention, but when the Global Ocean Development Forum plants its flag in Qingdao, even I sit up. We're talking about some real fireworks in the marine economy sector with this gig's '1+1+4+8' framework. Now, before you scratch your head on the bingo numbers—it's the opening...

Continue Reading
xTool X1: Redefining Laser Fabrication for Makers

Updated Category News Views 140

The Next Generation of Laser Fabrication Whenever a new gizmo hits the market, it's usually just an upgrade in disguise—faster, shinier, a touch more wattage. Not this time. xTool shook things up by rolling out the X1, a laser platform that gets what small businesses and makers truly crave: versatility and long-lasting potential. This bad boy does more than engrave; it...

Continue Reading
Hyundai and Texas Children's Boost Child Safety in Houston

Updated Category News Views 25

A Meaningful Partnership for Safer Houston Roads There's a good feeling about corporations genuinely pitching in for community welfare, and Hyundai teaming up with Texas Children's Hospital to boost child passenger safety around Houston is exactly that. Pairing philanthropy with safety is more than just a business move—it's a testament to human decency. With a $25,000...

Continue Reading
ZYNLONTA's Japanese Push: ADC Therapeutics Gains Traction

Updated Category News Views 33

ADC Therapeutics Eyes Japan with ZYNLONTA Bet These days, everyone seems to have their eyes on the Far East, and ADC Therapeutics is no exception. They're making a strategic leap by letting their budding blockbuster ZYNLONTA make waves in Japan. With the fresh file submitted for approval, it looks like they're hoping to capture market ground that could pay off big time...

Continue Reading
MGM China Hits Record Highs Amid Market Challenges

Updated Category News Views 79

Highs Amid Headwinds: MGM China's Standout Quarter Rolling into one's portfolio, MGM China isn't just coasting along—it's smashing some records, despite fierce headwinds. It's not all smooth sailing in Macau's gaming scene, but MGM China has hammered out its third-quarter results with gusto, setting new records for revenue and adjusted EBITDA. These folks aren't just...

Continue Reading
Jack Henry's Q1 2027 Deconversion Revenue Hits $17.9M

Updated Category News Views 0

Jack Henry Surprises with Strong Deconversion Revenue You're probably thinking, deconversion revenue—what on earth is that? Imagine you're in the financial tech business and one of your bigwig clients decides to merge or get gobbled up by another institution. They move shop, and voila, you've got some unexpected money flowing in due to that exit. That's deconversion...

Continue Reading
NEO Battery's Quarter: Converting Leads to Contracts

Updated Category News Views 0

NEO Battery's Bold Moves A glance at NEO Battery Materials Ltd.'s latest update feels like reading the playbook of a team stepping it up a notch. They're pushing those silicon-enhanced wonders into new territories—and doing so with one eye on expansion and the other on severe demand spikes from high-stakes sectors. From Leads to Customers No one's gonna raise eyebrows...

Continue Reading

Top 5 Most Recently Viewed Articles

AW Properties Global Announces Strategic Senior Living Development

Updated Category News Views 102

AW Properties Global Unveils New Opportunities in Real Estate AW Properties Global is excited to announce its latest offerings in the real estate market, focusing on two unique sites that present excellent opportunities for senior living and residential development. With a bid deadline approaching, this is an excellent chance for investors to explore promising projects....

Continue Reading
Invitation Homes Announces Major Notes Offering and Updates

Updated Category News Views 65

Invitation Homes Announces $500 Million Senior Notes Offering Invitation Homes Inc. (NYSE: INVH), a top player in the single-family home leasing sector, has made headlines with its recent announcement of a public offering for senior notes. This offering stands at $500 million and features 4.875% Senior Notes set to mature in 2035, priced at 98.855% of the principal...

Continue Reading
Sivers Semiconductors Strengthens Debt Structure with New Deal

Updated Category News Views 293

Revamping Debt: Sivers Takes Bold Steps Forward Got your eyes on Sivers Semiconductors? You should be. They just pulled off a significant refinancing deal that could reshape their financial landscape. On February 24, 2026, Sivers Semiconductors AB (STO:SIVE) announced securing a hefty USD 17 million with Bootstrap Europe. Details of the Loan Facility This move isn’t...

Continue Reading
Advanced Flower Capital Inc. Reports Strong Q1 Performance 2025

Updated Category News Views 143

Advanced Flower Capital's Impressive First Quarter Results In its first quarter results for 2025, Advanced Flower Capital Inc. (NASDAQ: AFCG) announced a noteworthy GAAP net income of $4.1 million, translating to $0.18 per basic weighted average common share. Additionally, the company's Distributable Earnings reached $4.5 million, or $0.21 per share. These figures...

Continue Reading
DMEGC Solar Unveils Groundbreaking PV Modules and Innovations

Updated Category News Views 255

DMEGC Solar Unveils New PV Modules at Major Exhibition DMEGC Solar has proudly established itself as a leader in the solar industry after receiving significant accolades at SNEC 2025. This prestigious event, regarded as one of the premier solar energy exhibitions globally, provided the perfect platform for the company to display its latest high-efficiency photovoltaic...

Continue Reading